Certolizumab pegol is effective for chronic plaque psoriasis across patient subgroups: A pooled subanalysis from ongoing phase 3 studies (CIMPASI-1, CIMPASI-2, and CIMPACT)

被引：0

作者：

Reich, Kristian ^{[1
]}

Gottlieb, Alice B. ^{[2
]}

Blauvelt, Andrew ^{[3
]}

Sofen, Howard ^{[4
]}

Weglowska, Jolanta ^{[5
]}

Augustin, Matthias ^{[6
]}

Poulin, Yves ^{[7
]}

Burge, Janice Drewof Danil ^{[8
]}

Peterson, Luke ^{[9
]}

Rolleri, Robert ^{[9
]}

Leonardi, Craig ^{[10
]}

机构：

[1] SCIderm Res Inst & Dermatol Hamburg, Hamburg, Germany

[2] New York Med Coll, Valhalla, NY 10595 USA

[3] Oregon Med Res Ctr, Portland, OR USA

[4] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[5] Niepubl Zaklad Opieki Zdrowotney MultiMed, Bialystok, Poland

[6] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[7] Ctr Rech Dermatol Quebec Metropolitain, Quebec City, PQ, Canada

[8] Dermira Inc, Menlo Pk, CA USA

[9] UCB BioSci Inc, Raleigh, NC USA

[10] Cent Dermatol, St Louis, MO USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2018年 / 79卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

7692

引用

页码：AB66 / AB66

页数：1

共 26 条

[21] Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies
Blauvelt, A.
Paul, C.
van de Kerkhof, P.
Warren, R. B.
Gottlieb, A. B.
Langley, R. G.
Brock, F.
Arendt, C.
Boehnlein, M.
Lebwohl, M.
Reich, K.
BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (04) : 640 - 651
[22] Bimekizumab efficacy for moderate to severe plaque psoriasis across patient subgroups: Pooled results from 3 multicenter, randomized, double-blinded phase 3 trials
Strober, Bruce
Warren, Richard B.
Foley, Peter
Gooderham, Melinda
Thaci, Diamant
Cullen, Eva
Cioffi, Christopher
Peterson, Luke
Madden, Cynthia
Armstrong, April
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB76 - AB76
[23] Insights into the efficacy and safety of tildrakizumab in patients with moderate-to-severe plaque psoriasis across age quartiles: Pooled analyses from the Phase 3 reSURFACE 1 and reSURFACE 2 trials
Elewski, Boni
Han, George
Rozzo, Stephen J.
Gogineni, Ranga
Schenkel, Brad
Guenthner, Scott
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB57 - AB57
[24] Pooled efficacy and safety results from the DERMIS-1 and DERMIS-2 phase 3 trials of once-daily roflumilast cream 0.3% for treatment of chronic plaque psoriasis
Lebwohl, Mark
Gooderham, Melinda J.
Guenthner, Scott T.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB93 - AB93
[25] Efficacy and safety of roflumilast cream 0.3% in patients with chronic plaque psoriasis: pooled PASI and PASI-HD results from the DERMIS-1 and DERMIS-2 Phase 3 Trials
Papp, Kim
Lebwohl, Mark
Hong, H. Chih-ho
Kircik, Leon
Pariser, David
Strober, Bruce
Krueger, Gerald
Krupa, David
Burnett, Patrick
Berk, David
Higham, Robert
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB156 - AB156
[26] Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis
Blauvelt, Andrew
Kircik, Leon
Schlesinger, Todd
Pierce, Evangeline
Burge, Russel
Behling, Michael
Atwater, Amber Reck
Elmaraghy, Hany
Armstrong, April
JOURNAL OF DERMATOLOGICAL TREATMENT, 2025, 36 (01)

← 1 2 3 →